the author has not received any funding or benefits from industry or elsewhere to conduct this study .
sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor . 
 the european medicines agency ( eama ) and food and drug administration ( fda ) approved the use of sorafenib in late - stage hepatic cellular cancer ( hcc ) on october 30 , 2007 , and november 19 , 2007 , respectively . 
 it is the only drug approved for use in the systematic treatment of primary hcc , and it offers renewed hope for middle- and late - stage liver cancer patients . conventional use of sorafenib is 400 mg orally , twice daily , until tumor progression or patient death . 
 the following is a report of a serious episode of skin rash in a liver cancer patient at our hospital subsequent to treatment with sorafenib .